Logo image of ZVSA

ZYVERSA THERAPEUTICS INC (ZVSA) Stock Fundamental Analysis

NASDAQ:ZVSA - Nasdaq - US98987D3008 - Common Stock - Currency: USD

0.6991  -0.01 (-1.89%)

After market: 0.6992 +0 (+0.01%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ZVSA. ZVSA was compared to 568 industry peers in the Biotechnology industry. While ZVSA seems to be doing ok healthwise, there are quite some concerns on its profitability. ZVSA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ZVSA has reported negative net income.
ZVSA had a negative operating cash flow in the past year.
ZVSA had negative earnings in each of the past 5 years.
ZVSA had a negative operating cash flow in each of the past 5 years.
ZVSA Yearly Net Income VS EBIT VS OCF VS FCFZVSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

ZVSA has a Return On Assets (-45.70%) which is comparable to the rest of the industry.
ZVSA's Return On Equity of -110.53% is in line compared to the rest of the industry. ZVSA outperforms 43.13% of its industry peers.
Industry RankSector Rank
ROA -45.7%
ROE -110.53%
ROIC N/A
ROA(3y)-182.17%
ROA(5y)-622.67%
ROE(3y)-364.67%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZVSA Yearly ROA, ROE, ROICZVSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

ZVSA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZVSA Yearly Profit, Operating, Gross MarginsZVSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, ZVSA has more shares outstanding
There is no outstanding debt for ZVSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ZVSA Yearly Shares OutstandingZVSA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
ZVSA Yearly Total Debt VS Total AssetsZVSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

ZVSA has an Altman-Z score of -9.58. This is a bad value and indicates that ZVSA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.58, ZVSA is doing worse than 73.06% of the companies in the same industry.
ZVSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.58
ROIC/WACCN/A
WACCN/A
ZVSA Yearly LT Debt VS Equity VS FCFZVSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 0.15 indicates that ZVSA may have some problems paying its short term obligations.
The Current ratio of ZVSA (0.15) is worse than 97.01% of its industry peers.
ZVSA has a Quick Ratio of 0.15. This is a bad value and indicates that ZVSA is not financially healthy enough and could expect problems in meeting its short term obligations.
ZVSA's Quick ratio of 0.15 is on the low side compared to the rest of the industry. ZVSA is outperformed by 96.83% of its industry peers.
Industry RankSector Rank
Current Ratio 0.15
Quick Ratio 0.15
ZVSA Yearly Current Assets VS Current LiabilitesZVSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

ZVSA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.43%, which is quite impressive.
EPS 1Y (TTM)99.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ZVSA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -21.81% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y93%
EPS Next 2Y33.34%
EPS Next 3Y-38.29%
EPS Next 5Y-21.81%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZVSA Yearly Revenue VS EstimatesZVSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 20M 40M 60M 80M
ZVSA Yearly EPS VS EstimatesZVSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ZVSA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZVSA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZVSA Price Earnings VS Forward Price EarningsZVSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZVSA Per share dataZVSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

ZVSA's earnings are expected to decrease with -38.29% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.34%
EPS Next 3Y-38.29%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZVSA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZYVERSA THERAPEUTICS INC

NASDAQ:ZVSA (4/17/2025, 8:00:02 PM)

After market: 0.6992 +0 (+0.01%)

0.6991

-0.01 (-1.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25 2025-03-25/amc
Earnings (Next)05-13 2025-05-13
Inst Owners3.49%
Inst Owner Change0%
Ins Owners0.08%
Ins Owner Change0%
Market Cap1.80M
Analysts82.5
Price Target122.4 (17408.22%)
Short Float %1.78%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)71.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.21
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-10.98
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)-2.94
FCFYN/A
OCF(TTM)-2.94
OCFYN/A
SpS0
BVpS3.31
TBVpS-3.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.7%
ROE -110.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-182.17%
ROA(5y)-622.67%
ROE(3y)-364.67%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.15
Quick Ratio 0.15
Altman-Z -9.58
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.8%
EPS Next Y93%
EPS Next 2Y33.34%
EPS Next 3Y-38.29%
EPS Next 5Y-21.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y36.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.31%
OCF growth 3YN/A
OCF growth 5YN/A